previous article next article
MIP nanoparticles targetting the HER2 receptor inhibit aggressive breast cancer cells
The use of MIPs in cancer medicine has been brought a step closer by the successful inhibition of the HER2 receptor on a particularly aggressive form of metastasising breast cancer cells. The nanoMIPs, targeting the glycans on the receptor protein, bind to HER2, and prevent the binding of growth factor, inhibiting the cells from proliferating. The effect has been demonstrated in vitro
and in vivo
(mice), showing inhibition in tumour growth. The report, from Zhen Liu and colleagues at Nanjing University, China is published in Angewandte Chemie International Edition
and features in a press release
as a hot paper from the journal.
Posted on 5 July 2019 at 13:44:42 by Michael Whitcombe
Log-in if you wish to post a comment.